+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

PRINTER FRIENDLY

Asia-Pacific Anticoagulants Market 2020-2026

  • ID: 5240978
  • Report
  • January 2021
  • Region: Asia Pacific
  • Orion Market Research Private Limited
UP TO OFF
until Dec 31st 2021

FEATURED COMPANIES

  • AstraZeneca plc
  • Bristol Myers Squibb Co.
  • Cipla Ltd.
  • Dr. Reddy's Laboratories
  • Lupin Ltd.
  • Novartis International AG
Asia-Pacific Anticoagulants Market Size, Share & Trends Analysis Report, By Type (Novel Oral Anticoagulants, Vitamin K Antagonist, and Heparin and Low Molecular Weight Heparin), By Application (Pulmonary Embolism, Atrial Fibrillation/Myocardial Infarction (Heart Attack), Deep Vein Thrombosis, and Others) and Forecast, 2020-2026.

Asia-Pacific anticoagulants market is estimated to grow at a CAGR of 7.8% during the forecast period. The rising prevalence of CVD is supporting to drive the adoption of anticoagulants in the region. CVD burden has been rising dramatically in the region owing to the rising aging population and rising prevalence of risk factors, including diabetes, hypertension, and smoking. The rising obese population is also a major risk factor for the rising CVD incidences in the region. The Chinese population is becoming increasingly overweight or obese, which has increased the risk of CVD in the country. This, in turn, is resulting in an increasing demand for anticoagulants that are used to prevent the blood from clotting as rapidly or as potentially as normal. Anticoagulants are also known as blood thinners. These medications are used for the treatment and prevention of blood clots that may occur in the blood vessels.

The market is segmented based on type and application. Based on type, the market is classified into novel oral anticoagulants (NOACs), vitamin k antagonist, and heparin, and low molecular weight heparin (LMWH). Increasing demand for NOACs has been reported in the region as it has demonstrated tremendous safety and efficacy without the requirement of subsequent dose adjustment and frequent monitoring. Based on application, the market is classified into a pulmonary embolism, atrial fibrillation/myocardial infarction (heart attack), deep vein thrombosis, and others.

Some key players in the market include Cipla Ltd., Bristol Myers Squibb Co., Pfizer Inc., Daiichi Sankyo Co. Ltd., and Boehringer Ingelheim GmbH. The market players are adopting some crucial strategies such as product launches and mergers and acquisitions. For instance, in June 2020, Gland Pharma Ltd. along with its partners Athenex Pharmaceutical Division and MAIA Pharmaceuticals Inc declared the introduction of a ready-to-use Bivalirudin injection in the US. This injection is intended for use as an anticoagulant among patients who are experiencing percutaneous coronary intervention (PCI), which includes patients suffering from heparin-induced thrombocytopenia and thrombosis syndrome, and heparin-induced thrombocytopenia.

Research Methodology

The market study of the Asia-Pacific anticoagulants market is incorporated by extensive primary and secondary research conducted by the research team. Secondary research has been conducted to refine the available data to breakdown the market into various segments, derive total market size, market forecast, and growth rate. Different approaches have been worked on to derive the market value and market growth rate. the team collects facts and data related to the market from different geography to provide a better regional outlook. In the report, the country-level analysis is provided by analyzing various regional players, regional tax laws and policies, consumer behavior, and macro-economic factors. Numbers extracted from Secondary research have been authenticated by conducting proper primary research. It includes tracking down key people from the industry and interviewing them to validate the data. This enables the analyst to derive the closest possible figures without any major deviations in the actual number. the analysts try to contact as many executives, managers, key opinion leaders, and industry experts. Primary research brings the authenticity in the reports.

Secondary Sources Include:
  • Financial reports of companies involved in the market.
  • Whitepapers, research-papers, and news blogs.
  • Company websites and their product catalog.
The report provides an in-depth analysis of market size, intended quality of the service preferred by consumers. The report will serve as a source for a 360-degree analysis of the market thoroughly integrating different models.

Market Segmentation:

1. Asia-Pacific Anticoagulants Market Research and Analysis by Type
2. Asia-Pacific Anticoagulants Market Research and Analysis by Application

The Report Covers:
  • Comprehensive research methodology of the Asia-Pacific anticoagulants market.
  • This report also includes a detailed and extensive market overview with key analyst insights.
  • An exhaustive analysis of macro and micro factors influencing the market guided by key recommendations.
  • Analysis of regional regulations and other government policies impacting the Asia-Pacific anticoagulants market.
  • Insights about market determinants that are stimulating the Asia-Pacific anticoagulants market.
  • Detailed and extensive market segments with regional distribution of forecasted revenues.
  • Extensive profiles and recent developments of market players.
Note: Product cover images may vary from those shown

FEATURED COMPANIES

  • AstraZeneca plc
  • Bristol Myers Squibb Co.
  • Cipla Ltd.
  • Dr. Reddy's Laboratories
  • Lupin Ltd.
  • Novartis International AG
1. Report Summary
1.1. Research Methods and Tools
1.2. Market Breakdown
1.2.1. By Segments
1.2.2. By Country

2. Market Overview and Insights
2.1. Scope of the Report
2.2. Analyst Insight & Current Market Trends
2.2.1. Key Findings
2.2.2. Recommendations
2.2.3. Conclusion

3. Market Determinants
3.1. Motivators
3.2. Restraints
3.3. Opportunities

4. Market Segmentation
4.1. Asia-PacificAnticoagulants Market by Type
4.1.1. Novel Oral Anticoagulants (NOACs)
4.1.2. Vitamin K Antagonist
4.1.3. Heparin and Low Molecular Weight Heparin (LMWH)
4.2. Asia-PacificAnticoagulants Market by Application
4.2.1. Pulmonary Embolism
4.2.2. Atrial Fibrillation/Myocardial Infarction (Heart Attack)
4.2.3. Deep Vein Thrombosis (DVT)
4.2.4. Others

5. Regional Analysis
5.1. China
5.2. India
5.3. Japan
5.4. Rest of Asia-Pacific

6. Company Profiles
6.1. AstraZeneca plc
6.1.1. Overview
6.1.2. Product Portfolio
6.1.3. Recent Activities
6.2. Bristol Myers Squibb Co.
6.3. Cipla Ltd.
6.4. Daiichi Sankyo Company, Ltd.
6.5. Dr. Reddy's Laboratories
6.6. Johnson & Johnson Services, Inc.
6.7. Lupin Ltd.
6.8. Novartis International AG
6.9. Pfizer Inc.
6.10. Sun Pharmaceutical Industries Ltd.
Note: Product cover images may vary from those shown
  • AstraZeneca plc
  • Bristol Myers Squibb Co.
  • Cipla Ltd.
  • Daiichi Sankyo Company, Ltd.
  • Dr. Reddy's Laboratories
  • Johnson & Johnson Services, Inc.
  • Lupin Ltd.
  • Novartis International AG
  • Pfizer Inc.
  • Sun Pharmaceutical Industries Ltd.
Note: Product cover images may vary from those shown
Adroll
adroll